Capricor Therapeutics (CAPR) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$24.6 million.
- Capricor Therapeutics' Income from Continuing Operations fell 9567.63% to -$24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 10498.83%. This contributed to the annual value of -$40.4 million for FY2024, which is 8059.67% down from last year.
- Capricor Therapeutics' Income from Continuing Operations amounted to -$24.6 million in Q3 2025, which was down 9567.63% from -$25.9 million recorded in Q2 2025.
- Over the past 5 years, Capricor Therapeutics' Income from Continuing Operations peaked at -$829093.0 during Q4 2023, and registered a low of -$25.9 million during Q2 2025.
- Over the past 5 years, Capricor Therapeutics' median Income from Continuing Operations value was -$7.2 million (recorded in 2023), while the average stood at -$9.3 million.
- As far as peak fluctuations go, Capricor Therapeutics' Income from Continuing Operations skyrocketed by 8921.39% in 2023, and later crashed by 74565.53% in 2024.
- Quarter analysis of 5 years shows Capricor Therapeutics' Income from Continuing Operations stood at -$6.4 million in 2021, then dropped by 20.79% to -$7.7 million in 2022, then surged by 89.21% to -$829093.0 in 2023, then crashed by 745.66% to -$7.0 million in 2024, then crashed by 250.44% to -$24.6 million in 2025.
- Its Income from Continuing Operations stands at -$24.6 million for Q3 2025, versus -$25.9 million for Q2 2025 and -$7.0 million for Q4 2024.